Wyeth Reports Earnings Results for the 2007 Third Quarter and First N...(the fastest growing product of the top 1...),Health

Prevnar(R), Wyeth's vaccine to prevent invasive pneumococcal disease in both infants and young children, continues to be the world's best-selling vaccine. Prevnar is now available in 86 countries. In September 2007, Wyeth filed a new drug application for Prevnar in Japan, the first step toward providing this important product to Japan's annual birth cohort of 1.1 million infants.

Effexor(R) (Effexor and Effexor XR) continues to be the number one selling antidepressant globally and an important therapy in treating adult patients with major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder. Effexor demonstrated its global strength during the 2007 third quarter by being the top selling antidepressant in 21 markets including the U.S., France and the United Kingdom.

Additional information regarding Wyeth's product sales may be accessed on the Company's Internet Web site at http://www.wyeth.com by clicking on the "Investor Relations" hyperlink.

2007 Third Quarter Results

Net income and diluted earnings per share for the 2007 third quarter were $1,145.9 million and $0.84, respectively, compared with $1,156.9 million and $0.85 for the 2006 third quarter. The 2007 third quarter results included charges of $117.1 million ($86.0 million after-tax or $0.06 per share-diluted) related to the Company's productivity initiatives. The 2006 third quarter results included charges of $80.2 million ($54.9 million after-tax or $0.04 per share-diluted) related to the Company's productivity initiatives and a favorable income tax adjustment of $70.4 million ($0.05 per share-diluted) related to the reduction of certain deferred tax asset valuation allowances. The 2007 and 2006 productivity initiatives charges and the 2006 income tax adjustment are considered to
'/>"/>